Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090932 · ClinicalTrials.gov registry record
Longitudinal Study of Innate Lymphoid Cells in Peripheral Blood in ALS
A clinical trial, sponsored by University of Michigan.
- Terminated
- Registry status
- 66
- Enrollment target
NCT03090932: Clinical Trial study, sponsored by University of Michigan.
NCT03090932 is a clinical trial that was terminated before completion, run by University of Michigan. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03090932 was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- 66 participants
- Enrollment target
Study Summary
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive muscle weakness and eventual death. Studies demonstrate that the immune system plays a key role in ALS progression; however, the role of the immune system is unclear, as various aspects can play both a beneficial and detrimental role in the disease course. Attempts to universally suppress the immune system in ALS patients have at best had negligible effects on progression or at worst accelerated the disease. Thus, there is a critical need to identify immune cell populations to serve as biomarkers and therapeutic targets.
Primary Outcome
Total number of classical NK cells; total number of CD3+ CD4+ CD8+ cells
Interventions
- OTHER Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-01-18 |
| Est. Completion | 2020-11-13 |
Why NCT03090932 stopped before completion
NCT03090932 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 66 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT03090932 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03090932 about?
NCT03090932 is a clinical study titled "Longitudinal Study of Innate Lymphoid Cells in Peripheral Blood in ALS". Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive muscle weakness and eventual death. Studies demonstrate that the immune system plays a key role in ALS progression; however, the role of the immune system is unclear, as various aspects can p...
What is the current status of trial NCT03090932?
This trial is currently terminated. The enrollment target is 66 participants. The study started on 2016-01-18. Estimated completion is 2020-11-13.
What interventions are being tested in trial NCT03090932?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT03090932?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI